This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: The University of Texas System. Active years: 2020-2022.
Company Filing History:
Years Active: 2020-2022
Title: The Innovations of Laurent Calvier
Introduction
Laurent Calvier is an accomplished inventor based in Austin, TX. He has made significant contributions to the field of medical research, particularly in the treatment of atherosclerosis. With a total of 2 patents to his name, Calvier's work focuses on innovative methods to improve cardiovascular health.
Latest Patents
Calvier's latest patents include groundbreaking inventions aimed at treating atherosclerosis. The first patent, titled "Reelin antibodies for treatment of atherosclerosis," provides methods and compositions for treating this condition. It involves the use of therapeutic compounds to reduce Reelin in the circulation of a subject, thereby decreasing the adhesion of leukocytes to the vascular wall. This invention also outlines methods for reducing leukocyte adhesion, which is crucial for improving vascular health. The second patent, "Methods and compositions for treatment of atherosclerosis," shares similar methodologies and compositions, emphasizing the importance of reducing Reelin levels to combat atherosclerosis effectively.
Career Highlights
Calvier is affiliated with the University of Texas System, where he conducts his research and develops his innovative solutions. His work has garnered attention for its potential impact on treating cardiovascular diseases, which are a leading cause of mortality worldwide.
Collaborations
Calvier has collaborated with notable colleagues in his field, including Joachim Herz and Yinyuan Ding. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Laurent Calvier's contributions to medical research through his patents on atherosclerosis treatment highlight his innovative spirit and dedication to improving health outcomes. His work continues to pave the way for advancements in cardiovascular therapies.